Literature DB >> 16014259

[Rational treatment of uncontrollable, life-threatening hemorrhage with recombinant factor VIIa].

Jakob Stensballe1, Stefan Lethagen, Freddy Lippert, Pär Ingemar Johansson.   

Abstract

We present a standardised treatment algorithm used to treat life-threatening haemorrhage (LTH) due to trauma, surgery, or delivery at Rigshospitalet, Copenhagen University Hospital. Balanced transfusion therapy and infusion of fibrinogen must precede recombinant factor VIIa (rFVIIa) treatment. rFVIIa is indicated in patients with uncontrollable LTH ( > 1 blood component per 10 kg of whole body weight per hour) despite surgical treatment and adequately balanced transfusion. We recommend rFVIIa at a dose of 100 microg/kg. The dosage recommendation is not evidence-based. A thorough, prospective surveillance program to monitor the treatment's efficacy and safety is therefore mandatory. The Blood Bank services, guides and coordinates the treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16014259

Source DB:  PubMed          Journal:  Ugeskr Laeger        ISSN: 0041-5782


  1 in total

1.  Recombinant factor VIIa: hemostatic adjunct in the coagulopathic burn patient.

Authors:  Jeremiah T Martin; Fuad Alkhoury; Bryan C McIntosh; Phillip Fidler; John Schulz
Journal:  Eplasty       Date:  2009-07-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.